Company intelligence / Profile preview

Neogap Therapeutics

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Neogap Therapeutics has reported initial safety data from its ongoing phase I/II trial of its personalized immunotherapy product pTTL in colorectal cancer. The treatment has shown a positive safety profile with no serious treatment-related adverse events observed so far[1].

Therapeutic areas: Oncology
Modalities: Cell therapy (autologous T cell therapy)Immunotherapy
Industry: Biotech

Drug pipeline

1 asset

pTTL

Partnerships

NorthX Biologics (manufacturing partnership)[6]Okomera (Eurostars-funded collaboration project)[4]

Beyond the preview

Go deeper on Neogap Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neogap Therapeutics.

Explore the full profile